



## Emerging Topics in Leishmaniasis Research

Guest Editor:

### **Dr. Sandra Regina Maruyama**

Departamento de Genética e  
Evolução, Centro de Ciências  
Biológicas e da Saúde,  
Universidade Federal de São  
Carlos-UFSCar, São Carlos 13565-  
905, Brazil

Deadline for manuscript  
submissions:

**closed (30 July 2023)**

### **Message from the Guest Editor**

Leishmaniasis are vector-borne parasitic diseases caused by dixerous trypanosomatids from the Leishmaniinae subfamily. The three main clinical forms of these diseases are visceral, cutaneous and mucocutaneous. Visceral leishmaniasis is a systemic disease mainly affecting tissues, such as bone marrow, spleen and liver; it is fatal for most untreated or misdiagnosed cases. Cutaneous form is characterized by ulcerative skin lesions in exposed body parts, and is the most common form of Leishmaniasis. The mucocutaneous form is characterized by destructive lesions in mucosal membranes of mouth, throat and nose. These diseases can cause serious disability, life-long scars and stigma since they are heavily associated with poverty and its impact. Leishmaniasis are complex diseases involving a wide range of species in parasite, vector sand fly, and natural reservoir hosts. There is no licensed vaccine for humans, prevention and control measures are limited, and available treatment drugs have a high toxicity with many side effects. Diagnosis is primarily clinical and is usually confirmed using serological devices that have a high cross-reactivity with other trypanosomatids.

